CN109453154A - A kind of inhibitor of PD-L1 and preparation method thereof - Google Patents
A kind of inhibitor of PD-L1 and preparation method thereof Download PDFInfo
- Publication number
- CN109453154A CN109453154A CN201710794378.7A CN201710794378A CN109453154A CN 109453154 A CN109453154 A CN 109453154A CN 201710794378 A CN201710794378 A CN 201710794378A CN 109453154 A CN109453154 A CN 109453154A
- Authority
- CN
- China
- Prior art keywords
- preparation
- culture medium
- protein
- bromine
- palmitinic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses the preparation that PD-L1 protein expression quantity in a kind of inhibition tumour cell and reduction PD-L1 protein are distributed in cell membrane localization, 2- bromine palmitinic acid, the fetal calf serums, culture medium for being 10uM~100uM comprising molar concentration；Preparation method includes: the culture medium of concentrate and preparation containing fetal calf serum for preparing 2- bromine palmitinic acid, and then 2- bromine palmitinic acid concentrate is added in the culture medium containing fetal calf serum；The preparation that PD-L1 protein expression quantity and reduction PD-L1 protein are distributed in cell membrane localization in the inhibition tumour cell of technical solution of the present invention, expression of the PD-L1 protein in tumour cell can be reduced, and PD-L1 is reduced in the positioning of cancer cell membrane, there is dual PD-L1 inhibiting effect；The immune response for being conducive to activate T cell, improves tumor immunity, will have a wide range of applications in the biomedicine and study of pharmacy of PD-L1 regulation.
Description
Technical field
The present invention relates to biopharmaceutical technologies, and in particular to one kind is for inhibiting PD-L1 protein expression quantity and thin
The preparation and preparation method thereof of after birth positioning.
Background technique
Malignant tumour is a kind of disease that China's morbidity and mortality are occupied the forefront, and clinical diagnosis in recent years performs the operation, puts
The development of chemotherapy is so that a part of malignant tumor patient obtains early detection and effectively treatment.However in worldwide, seek
Looking for new treatment method and drug is the hot spot in tumor research field for a long time.Different from traditional treatment method, tumour is exempted from
Epidemic disease treatment can activate or induce human body to set up the specific immune response to tumour antigen, remove primary or transfer tumour
Cell, and immunological memory is established, recurrence, drug resistance and the transfer of tissue tumor.Apoptosis molecule 1 (PD-L1) is to exempt from
One of epidemic disease checkpoint albumen plays a major role in restricted T cells activity, and affiliated T cell provides main immune resistance
Mechanism can escape immunosurveillance by this restriction effect tumour cell.The PD-1 that is expressed in the T cell of activation with swollen
The interaction of the PD-L1 expressed on oncocyte plays negative regulator to immune response and weakens anti-tumor immunity.PD-L1 is in tumour
On expression it is related to the decline of the survival rate of melanoma, lung cancer, the cancer of the esophagus and other types of cancer, highlight the access into
Row PD-L1 inhibits excessively expression to can be used as new promising immunotherapy of tumors target spot.
Currently, having there is drugmaker to have developed the antibody of targeting PD-L1, shows and face in different tumor types
Bed activity.PD-L1 antibody is by conjunction with PD-L1, blocking the combination of PD-L1 and PD-1 in cell surface and activating T cell
Immune response improves anti-tumor immunity.But expression quantity and reduction for PD-L1, it is not directly changed the film of PD-L1 yet
Positioning.There are still very big challenge and shortcomings for the current this immunologic test point Blocking therapy based on PD-L1 antibody, such as have
Partial tumors patient reacts unsatisfactory curative effect to PD-L1 Antybody therapy, the effect for the treatment of be also possible to the extension with administration time and
It decreases.Therefore the novel formulation or method inhibited to research targeting PD-L1, the curative effect for further improving tumor patient exist very
Big demand.
Therefore, those skilled in the art is dedicated to developing a kind of inhibition PD-L1 protein expression quantity and cell membrane localization
Preparation, activate the immune response of T cell, improve tumor immunity, it is anti-to PD-L1 to solve above-mentioned tumor patient in the prior art
In place of the deficiencies of body therapeutic response unsatisfactory curative effect.
Summary of the invention
In view of the drawbacks described above of the prior art, the purpose of the present invention is to solve the shortcomings of the prior art and to treatment tumour
Demand, solve it is existing based on PD-L1 antibody with PD-L1 ining conjunction with and activate the immune response of T cell, resist to reach and improve
The problems such as there are unsatisfactory curative effects in the method for anti-tumor immunity.There is provided one kind can reduce PD-L1 protein in tumour cell
Expression quantity, and can be reduced preparation, preparation method and application that PD-L1 protein is distributed in cell membrane localization.
To achieve the above object, the first aspect of the present invention provides a kind of inhibition PD-L1 protein expression quantity and reduces PD-
The preparation that L1 protein is distributed in cell membrane localization, is achieved through the following technical solutions:
It is a kind of to inhibit PD-L1 protein expression quantity and reduce the preparation that PD-L1 protein is distributed in cell membrane localization, include
Molar concentration (mol/L) is the 2- bromine palmitinic acid of 10uM~100uM.
Further, the preparation includes following components: the 2- bromine palm fibre that molar concentration (mol/L) is 10uM~100uM
Palmitic acid acid, fetal calf serum；
Further, the weight percentage of the fetal calf serum in the formulation is 5%~20%；It is preferred that 10%~
20%；
Further, the preparation includes following components: the 2- bromine palm fibre that molar concentration (mol/L) is 10uM~100uM
Palmitic acid acid, the fetal calf serum that weight percentage is 5%~20%, culture medium；
Further, the culture medium is conventional liq culture medium；It is preferred that DMEM culture medium, RPMI1640 culture medium；
Second aspect of the present invention provides a kind of inhibition PD-L1 protein expression quantity and reduces PD-L1 protein in cell membrane
Position the preparation method of the preparation of distribution, comprising the following steps:
Step 1, the concentrate for preparing 2- bromine palmitinic acid, packing freezing；
Step 2, culture medium of the preparation containing fetal calf serum；
Step 1 is obtained 2- bromine palmitinic acid concentrate and is added in the culture medium containing fetal calf serum of step 2 by step 3,
The preparation that the PD-L1 protein expression quantity that is inhibited and reduction PD-L1 protein are distributed in cell membrane localization.
Third aspect present invention additionally provide any one of first aspect present invention inhibition PD-L1 protein expression quantity and
It reduces PD-L1 protein and is preparing the purposes in PD-L1 inhibitory preparation in the preparation that cell membrane localization is distributed.
The present invention also provides any one of first aspect present invention inhibition PD-L1 protein expression quantity and reduce PD-
L1 protein is in the preparation that cell membrane localization is distributed in preparation treatment and the purposes in PD-L1 inhibition related disease.
The present invention also provides a kind of methods for the treatment of and PD-L1 inhibition related disease comprising to subject in need
It applies any one of a effective amount of first aspect present invention inhibition PD-L1 protein expression quantity and reduces PD-L1 protein and exist
The preparation of cell membrane localization distribution；
It is described above to inhibit related disease to be selected from tumour with PD-L1.
The preparation that inhibition PD-L1 protein expression quantity and reduction PD-L1 protein of the invention is distributed in cell membrane localization
PD-L1 protein expression quantity in tumour cell can be reduced, while reducing PD-L1 and being distributed in the positioning of cell membrane, since tumour is thin
The Function of the PD-L1 of born of the same parents depends on normal expression and cell membrane localization, therefore there is invention formulation dual PD-L1 to press down
Production is used, and PD-L1 expression quantity on tumour cell is reduced, and reduces the interaction with the PD-1 expressed in the T cell of activation, from
And be conducive to activate T cell immune response and play positive control, enhance anti-tumor immunity.
Compared with the prior art middle PD-L1 antibody reduced and in conjunction with the PD-L1 of tumour cell film surface PD-L1 with
The interaction of PD-1 combines unsatisfactory curative effect existing for there are PD-L1 antibody due to individual difference, and exists because of administration time
Extension and defect that curative effect decreases；Inhibition PD-L1 protein expression quantity and reduction PD-L1 protein of the invention is thin
The preparation of after birth positioning distribution directly inhibits and reduces the expression quantity of PD-L1, has fundamentally blocked that PD-L1's and PD-1 is mutual
Effect has better inhibiting effect and therapeutic effect.
In conclusion inhibition PD-L1 protein expression quantity of the invention and reduction PD-L1 protein are in cell membrane localization point
The preparation of cloth has dual PD-L1 inhibiting effect, is conducive to activate T cell immune response and improves tumor immunity, as
The new breakthrough of immunotherapy of tumors method, said preparation have extensive in the biomedicine and study of pharmacy for PD-L1 regulation
Meaning.
Detailed description of the invention
Fig. 1 is the expression quantity gel figure of the PD-L1 in embodiment 5 under different time；
Fig. 2 is the expression quantity gel figure of the PD-L1 in embodiment 6 under various concentration；
Fig. 3 is the PD-L1 cell membrane localization figure in embodiment 7 under different time；
Wherein, in Fig. 3, ellipticity spot is DAPI；At arrow instruction, the irregular shape spot around DAPI is
PD-L1。
Specific embodiment
Raw material, equipment used in the specific embodiment of the invention are known product, are obtained by purchase commercial product.
The chemical structural formula of 2- bromine palmitinic acid in technical solution of the present invention are as follows:
The present invention provides a kind of inhibition PD-L1 protein expression quantity and PD-L1 protein is reduced in cell membrane localization point
The preparation of cloth；Wherein, comprising molar concentration (mol/L) be 25uM~80uM 2- bromine palmitinic acid, weight percentage be
10%~20% fetal calf serum, culture medium.
In preferrred embodiment of the present invention, the culture medium is DMEM culture medium, RPMI1640 culture medium；
In preferrred embodiment of the present invention, the inhibition PD-L1 protein expression quantity and reduction PD-L1 protein exist
The preparation of cell membrane localization distribution；
Wherein, 2- bromine palmitinic acid, the weight percentage 10% for being 25uM~80uM comprising molar concentration (mol/L)
~20% fetal calf serum, DMEM culture medium；
In preferrred embodiment of the present invention, the inhibition PD-L1 protein expression quantity and reduction PD-L1 protein exist
The preparation of cell membrane localization distribution；
Wherein, 2- bromine palmitinic acid, the weight percentage 10% for being 25uM~80uM comprising molar concentration (mol/L)
~20% fetal calf serum, RPMI1640 culture medium；
In preferrred embodiment of the present invention, the molar concentration (mol/L) of the 2- bromine palmitinic acid be 50uM~
80uM；
In preferrred embodiment of the present invention, the molar concentration (mol/L) of the 2- bromine palmitinic acid is 50uM.
The present invention provides a kind of inhibition PD-L1 protein expression quantity and PD-L1 protein is reduced in cell membrane localization point
The preparation method of the preparation of cloth, comprising the following steps:
2- bromine palmitinic acid is dissolved in solvent by step 1, prepares the concentrate of 2- bromine palmitinic acid, dispenses freezen protective；
The fetal calf serum that weight percentage is 10%~20% is added in culture medium step 2, is prepared containing tire
The culture medium of cow's serum；
Step 3, step 1 is obtained 2- bromine palmitinic acid concentrate be added to step 2 containing weight percentage 10%~
In the culture medium of 20% fetal calf serum, the PD-L1 protein expression quantity that is inhibited and reduction PD-L1 protein are fixed in cell membrane
The preparation of bit distribution.
In preferrred embodiment of the present invention, in the step 1, the solvent is solvent miscible with water, preferably second
Alcohol, dimethyl sulfoxide；
In preferrred embodiment of the present invention, in the step 1, the molar concentration of the concentrate of 2- bromine palmitinic acid (is rubbed
You/liter) it is 10mM~200mM；It is preferred that 80mM~150mM；Most preferably 100mM；
In preferrred embodiment of the present invention, in the step 1, the temperature of freezen protective is -40 DEG C~-100 DEG C；It is excellent
- 60 DEG C~-80 DEG C of choosing；Most preferably -80 DEG C；
In preferrred embodiment of the present invention, in the step 2, culture medium is that DMEM culture medium or RPMI1640 are cultivated
Base；
In preferrred embodiment of the present invention, in the step 3, obtained inhibition PD-L1 protein expression quantity and subtract
Few PD-L1 protein 2- bromine palmitinic acid molar concentration (mol/L) in the preparation that cell membrane localization is distributed be preferably 25uM~
80uM；Further preferably 50uM~80uM；Most preferably 50uM；
The present invention provides the following aspect purposes or method of a kind of above-mentioned preparation:
Inhibit PD-L1 protein expression quantity and reduces purposes of the PD-L1 protein in cell membrane localization distribution；
Preparing the purposes in PD-L1 inhibitory preparation；
In preparation treatment and the purposes in PD-L1 inhibition related disease；
Inhibit the method for related disease with PD-L1 in treatment comprising apply a effective amount of to subject in need
Invent above-mentioned preparation；
In preferrred embodiment of the present invention, the purposes or method are realized by following steps:
Present invention preparation processing cancer cell obtained above is taken, then point collects cell pyrolysis liquid in different times, uses
The expression quantity of gel electrophoresis and western blotting method detection PD-L1, with the increase of the dosage of the extension and preparation of time,
The expression quantity presentation of PD-L1 protein gradually decreases trend；
Present invention preparation processing cancer cell obtained above is taken, then with the fixed cell of formaldehyde, using PD-L1 antibody to thin
Born of the same parents carry out immunofluorescence dyeing label, using the positioning scenarios of Laser Scanning Confocal Microscope detection PD-L1 in the cell.
Elaborate below with reference to embodiment to technical solution of the present invention: the present embodiment is with technical solution of the present invention
Premised under implemented, the detailed implementation method and specific operation process are given, but protection scope of the present invention is unlimited
In following embodiments.
Embodiment 1 inhibits PD-L1 protein expression quantity and reduces the preparation that PD-L1 protein is distributed in cell membrane localization
The preparation of (2-BP)
2- bromine palmitinic acid is dissolved in ethyl alcohol by step 1 with 10mM molar concentration, and the concentration of 2- bromine palmitinic acid is prepared
Liquid is protected from light, and -60 DEG C~-80 DEG C freezen protectives, avoid multigelation after packing；
The fetal calf serum that weight percentage is 10%~20% is added in DMEM culture medium step 2, is prepared and contains
There is the culture medium of 10%~20% fetal calf serum；
Step 3, step 1 is obtained 2- bromine palmitinic acid concentrate be added to step 2 containing weight percentage 10%~
In the culture medium of 20% fetal calf serum, the inhibition PD-L1 albumen that 2- bromine palmitinic acid molar concentration (mol/L) is 10uM is obtained
The preparation (2-BP) that matter expression quantity and reduction PD-L1 protein are distributed in cell membrane localization.
The preparation of embodiment 2,2-BP
2- bromine palmitinic acid is dissolved in dimethyl sulfoxide by step 1 with 80mM molar concentration, and 2- bromine palmitinic acid is prepared
Concentrate, be protected from light, -80 DEG C~-100 DEG C freezen protectives, avoid multigelation after packing；
The fetal calf serum that weight percentage is 5%~10% is added in RPMI1640 culture medium step 2, is prepared into
To the culture medium containing 5%~10% fetal calf serum；
Step 3, step 1 is obtained 2- bromine palmitinic acid concentrate be added to step 2 containing weight percentage 5%~
In the culture medium of 10% fetal calf serum, the inhibition PD-L1 albumen that 2- bromine palmitinic acid molar concentration (mol/L) is 80uM is obtained
The preparation (2-BP) that matter expression quantity and reduction PD-L1 protein are distributed in cell membrane localization.
The preparation of embodiment 3,2-BP
2- bromine palmitinic acid is dissolved in ethyl alcohol by step 1 with 100mM molar concentration, and the dense of 2- bromine palmitinic acid is prepared
Contracting liquid, is protected from light, and -80 DEG C of freezen protectives after packing avoid multigelation；
The fetal calf serum that weight percentage is 10%~20% is added in DMEM culture medium step 2, is prepared and contains
There is the culture medium of 10%~20% fetal calf serum；
Step 3, step 1 is obtained 2- bromine palmitinic acid concentrate be added to step 2 containing weight percentage 10%~
In the culture medium of 20% fetal calf serum, the inhibition PD-L1 albumen that 2- bromine palmitinic acid molar concentration (mol/L) is 50uM is obtained
The preparation (2-BP) that matter expression quantity and reduction PD-L1 protein are distributed in cell membrane localization.
The preparation of embodiment 4,2-BP
2- bromine palmitinic acid is dissolved in dimethyl sulfoxide by step 1 with 150mM molar concentration, and 2- bromine palm is prepared
The concentrate of acid, is protected from light, -40 DEG C~-60 DEG C freezen protectives, avoid multigelation after packing；
The fetal calf serum that weight percentage is 10%~20% is added in RPMI1640 culture medium step 2, is prepared into
To the culture medium containing 10%~20% fetal calf serum；
Step 3, step 1 is obtained 2- bromine palmitinic acid concentrate be added to step 2 containing weight percentage 10%~
In the culture medium of 20% fetal calf serum, the inhibition PD-L1 albumen that 2- bromine palmitinic acid molar concentration (mol/L) is 25uM is obtained
The preparation (2-BP) that matter expression quantity and reduction PD-L1 protein are distributed in cell membrane localization.
Test example 5,
2-BP that Example 3 obtains handles Human Colorectal Cancer cell RKO, 0 hour, 1 hour, 3 hours, 6 hours,
The cell pyrolysis liquid that above-mentioned treated Human Colorectal Cancer cell is collected at 12 hours, 24 hours, using GAPDH in
Ginseng, with the expression quantity of gel electrophoresis and western blotting method detection PD-L1.
As a result as shown in Fig. 1, it is small that the expression quantity for the PD-L1 protein that 6 hours, 12 hours whens detect is considerably less than 0
The expression quantity of PD-L1 protein constantly；At 24 hours detected through gel electrophoresis to PD-L1 protein expression quantity scar disappear substantially
It loses, illustrates the amount of the PD-L1 protein expression at 24 hours below the minimum magnitude that gel electrophoresis can be detected；Show with
The extension of time, in the cell pyrolysis liquid of the processed Human Colorectal Cancer cell RKO of 2-BP by embodiment 3, PD-L1 egg
The expression quantity presentation of white matter gradually decreases trend.
Test example 6,
The concentration that Example 1, embodiment 4, embodiment 3 obtain is respectively the 2-BP processing mankind of 10uM, 25uM, 50uM
Colorectal cancer cell RKO collects the cell pyrolysis liquid of above-mentioned treated Human Colorectal Cancer cell after 24 hours, with
GAPDH is as internal reference, with the expression quantity of gel electrophoresis and western blotting method detection PD-L1.
As a result as shown in Fig. 2, relative to the Human Colorectal Cancer cell pyrolysis liquid for 2-BP not being added to be handled, concentration is
In the 2-BP of 10uM treated Human Colorectal Cancer cell pyrolysis liquid, PD-L1 protein expression quantity is reduced, and concentration is 25uM's
The 2-BP that 2-BP treated Human Colorectal Cancer cell pyrolysis liquid and concentration are 50uM treated Human Colorectal Cancer cell
In lysate, PD-L1 protein expression quantity is further decreased；Show the raising with 2-BP concentration, it is processed by 2-BP
In the cell pyrolysis liquid of Human Colorectal Cancer cell RKO, the expression quantity presentation of PD-L1 protein gradually decreases trend.
Test example 7,
(1), the 2-BP that Example 3 obtains handled Human Colorectal Cancer cell RKO, at 3 hours, 9 hours, 18 hours
Sampling carries out subsequent processing detection；
(2), cell is fixed 20 minutes with 4% formaldehyde for being dissolved in PBS again after rinsing sample in upper step cell 2 times with PBS,
The PBS containing 0.2%Triton X100 and 1%BSA is added and carries out permeable membrane and closing 1 hour；
(3), by permeable membrane confining liquid in upper step according to being incubated for again after the dilution proportion of 1:200 45-60 minutes；
(4), sample obtained in upper step is washed cell 3 times with PBS, every time after five minutes, with PBS according to 1:250 to 1:
1000 dilution secondary antibodies therein, then incubation 20-30 minutes is protected from light according to 1:5000 with DAPI；
(5), sample in upper step is washed cell 3 times with PBS, every time after five minutes, is sealed with the anti-quencher of Prolong Gold
Piece, fluorescence microscopy is under the microscope.
After PD-L1 is marked in above step, using the positioning feelings of Laser Scanning Confocal Microscope detection PD-L1 in the cell
As a result as shown in Fig. 3 condition compared with the cell liquid of the Human Colorectal Cancer cell for the 2-BP that embodiment 3 is not added, is being added
In Human Colorectal Cancer cell behind 3 hours of the 2-BP of embodiment 3,9 hours and 18 hours, PD-L1 is on cell membrane
Disappearance trend is presented in positioning, and positioning of the PD-L1 on cell membrane can be observed after 18 hours and disappear；Show by the present embodiment
3 2-BP it is processed in the cell pyrolysis liquid of Human Colorectal Cancer cell, tumour cell significantly reduces the cell membrane of PD-L1
Positioning, further suppresses the expression of PD-L1, reduces PD-L1 protein expression quantity.
In conclusion the inhibition PD-L1 protein expression quantity of technical solution of the present invention and reduction PD-L1 protein are in cell
The preparation of film positioning distribution, can reduce simultaneously the expression quantity of PD-L1, and reduce PD-L1 in the positioning of cancer cell membrane, have dual
PD-L1 inhibiting effect.The immune response for being conducive to activate T cell, improves tumor immunity, as new immunotherapy of tumors
Method, has a very important significance and application value.
Specific embodiments of the present invention are described in detail above.It should be appreciated that the ordinary skill of this field is without creativeness
Labour, which according to the present invention can conceive, makes many modifications and variations.Therefore, all structures under this invention in the art
Think the technical solution obtained on the basis of existing technology by logical analysis, reasoning, or a limited experiment, it all should be in right
In protection scope determined by claim.
Claims (10)
1. a kind of inhibit PD-L1 protein expression quantity and reduce the preparation that PD-L1 protein is distributed in cell membrane localization, feature
It is, the 2- bromine palmitinic acid for being 10uM~100uM comprising molar concentration.
2. preparation according to claim 1, which is characterized in that include following components: molar concentration is the 2- of 10uM~100uM
Bromine palmitinic acid, fetal calf serum；
Wherein, the weight percentage of the fetal calf serum is 5%~20%.
3. preparation according to claim 2, which is characterized in that include following components: molar concentration is the 2- of 25uM~80uM
Bromine palmitinic acid, the fetal calf serum that weight percentage is 5%~20%, culture medium.
4. preparation according to claim 3, which is characterized in that
The molar concentration of the 2- bromine palmitinic acid is 50uM~80uM；It is preferred that 50uM；
The weight percentage of the fetal calf serum is 10%~20%；
The culture medium is DMEM culture medium or RPMI1640 culture medium.
5. a kind of preparation for inhibiting PD-L1 protein expression quantity and reducing the preparation that PD-L1 protein is distributed in cell membrane localization
Method, comprising the following steps:
Step 1, the concentrate for preparing 2- bromine palmitinic acid, packing freezing；
Step 2, culture medium of the preparation containing fetal calf serum；
Step 1 is obtained 2- bromine palmitinic acid concentrate and is added in the culture medium containing fetal calf serum of step 2 by step 3, is obtained
Inhibit PD-L1 protein expression quantity and reduces the preparation that PD-L1 protein is distributed in cell membrane localization.
6. method according to claim 5, which comprises the following steps:
2- bromine palmitinic acid is dissolved in solvent by step 1, prepares the concentrate of 2- bromine palmitinic acid, dispenses freezen protective；
The fetal calf serum that weight percentage is 10%~20% is added in culture medium step 2, is prepared containing tire ox blood
Clear culture medium；
Step 3, step 1 is obtained 2- bromine palmitinic acid concentrate be added to step 2 containing weight percentage 10%~20%
Fetal calf serum culture medium in, the PD-L1 protein expression quantity that is inhibited and reduce PD-L1 protein in cell membrane localization point
The preparation of cloth.
7. method according to claim 6, which is characterized in that in the step 1,
The solvent is solvent miscible with water, is selected from ethyl alcohol, dimethyl sulfoxide；
The molar concentration of the concentrate of the 2- bromine palmitinic acid is 10mM~200mM；It is preferred that 80mM~150mM；Most preferably
100mM；
The temperature of the freezen protective is -40 DEG C~-100 DEG C；It is preferred that -60 DEG C~-80 DEG C；Most preferably -80 DEG C；
In the step 2, culture medium is DMEM culture medium or RPMI1640 culture medium.
8. any one of the claim 1-4 inhibition PD-L1 protein expression quantity and reduction PD-L1 protein are in cell membrane localization
The preparation of distribution is preparing the purposes in PD-L1 inhibitory preparation.
9. any one of the claim 1-4 inhibition PD-L1 protein expression quantity and reduction PD-L1 protein are in cell membrane localization
The preparation of distribution is in preparation treatment and the purposes in PD-L1 inhibition related disease.
10. a kind of method that treatment inhibits related disease with PD-L1 comprising apply a effective amount of power to subject in need
Benefit requires any one of 1-4 is described to inhibit PD-L1 protein expression quantity and reduce the system that PD-L1 protein is distributed in cell membrane localization
Agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710794378.7A CN109453154A (en) | 2017-09-06 | 2017-09-06 | A kind of inhibitor of PD-L1 and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710794378.7A CN109453154A (en) | 2017-09-06 | 2017-09-06 | A kind of inhibitor of PD-L1 and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109453154A true CN109453154A (en) | 2019-03-12 |
Family
ID=65605869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710794378.7A Pending CN109453154A (en) | 2017-09-06 | 2017-09-06 | A kind of inhibitor of PD-L1 and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109453154A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104918602A (en) * | 2012-12-20 | 2015-09-16 | Elc管理有限责任公司 | Modulation of melanogenesis by modification of tyrosinase by palmitoylation |
-
2017
- 2017-09-06 CN CN201710794378.7A patent/CN109453154A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104918602A (en) * | 2012-12-20 | 2015-09-16 | Elc管理有限责任公司 | Modulation of melanogenesis by modification of tyrosinase by palmitoylation |
Non-Patent Citations (3)
| Title |
|---|
| RESH, MD: "Palmitoylation of proteins in cancer", 《BIOCHEMICAL SOCIETY TRANSACTIONS》 * |
| YAO, HAN等: "Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours", 《NATURE BIOMEDICAL ENGINEERING》 * |
| 胡桂学等: "《兽医微生物学实验教程》", 31 January 2015, 北京：中国农业大学出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107582550B (en) | Application of the datro in treatment colorectal cancer | |
| CN110194787A (en) | Active polypeptide of targeted inhibition Wnt/ β-catenin signal and application thereof | |
| Zhang et al. | The effect of c-fos on acute myocardial infarction and the significance of metoprolol intervention in a rat model | |
| CN109125324A (en) | Acyl-CoA: the new application of Cholesteryl acyltransferase 1 inhibitor | |
| CN106565587A (en) | AURKB small-molecule inhibitor and application thereof | |
| CN106963765B (en) | Application of EZH2 inhibitor compound in preparation of medicine for treating ocular melanoma | |
| CN102391992A (en) | Monoclonal antibody for resisting human NSCLC and application of monoclonal antibody | |
| CN103923212A (en) | EHD2 antibody and application of EHD2 antibody to preparation of immunohistochemical detection reagent for breast cancer | |
| CN109453154A (en) | A kind of inhibitor of PD-L1 and preparation method thereof | |
| CN104271583B (en) | The method for treating nasopharyngeal carcinoma | |
| CN106435002B (en) | Oral squamous cell carcinoma biomarker and its application | |
| CN112094268B (en) | Compound WEZ series, preparation method thereof and application of compound WEZ series in preparation of medicines | |
| CN104045682A (en) | Holothuria moebii saponin A, and preparation and application thereof | |
| CN104151392A (en) | Moebioside A as well as preparation and application thereof | |
| CN113476466A (en) | Application of baicalin in preparation of drug resistant to chronic myeloid leukemia | |
| CN101870720A (en) | Preparation method of ursolic acid and application thereof to medicine treating tumor diseases | |
| CN105585627A (en) | Antigen polypeptide and application of anti-GBM nephritis model built from same | |
| CN109364045A (en) | A kind of inhibitor of heat shock protein 90 and the application in terms of liver cancer treatment | |
| CN109975499A (en) | A kind of detection method promoting Ritonavir drug anticancer validity | |
| CN101161283A (en) | New use of CMTM1-v17 and its antagon | |
| CN109745314A (en) | Application of the iron chelating agent Deferasirox (DFX) in the drug for the treatment of cervical carcinoma | |
| TWI465241B (en) | Use of an extract of juniperus chinensis or lignan for manufacturing a medicament for inhibiting angiogenesis | |
| CN109053480A (en) | The preparation method of a kind of novel niclosamide derivative and the application in oncotherapy | |
| CN103610683B (en) | DPPA is preparing the application in antitumor drug | |
| RU2352947C1 (en) | Method of diagnostics of autoimmune violent dermatoses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190312 |